医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
17期
356-357
,共2页
余凤%张幸平(通讯作者)
餘鳳%張倖平(通訊作者)
여봉%장행평(통신작자)
非小细胞肺癌%分子靶向治疗%放射治疗%化疗
非小細胞肺癌%分子靶嚮治療%放射治療%化療
비소세포폐암%분자파향치료%방사치료%화료
non-smal cel lung cancer%molecular targeted therapy%radiotherapy%chemotherapy
目前非小细胞肺癌（non-smal cel lung cancer，NSCLC）的治疗方法呈现个体化趋势，以弥补传统的手术、放疗、化疗临床疗效的不足。分子靶向治疗目前已成为NSCLC患者综合治疗的重要选择之一。分子靶向药物对患者有选择性，临床应用中耐受性较好，与放疗、化疗联合能增加其敏感性，提高治疗有效率。
目前非小細胞肺癌（non-smal cel lung cancer，NSCLC）的治療方法呈現箇體化趨勢，以瀰補傳統的手術、放療、化療臨床療效的不足。分子靶嚮治療目前已成為NSCLC患者綜閤治療的重要選擇之一。分子靶嚮藥物對患者有選擇性，臨床應用中耐受性較好，與放療、化療聯閤能增加其敏感性，提高治療有效率。
목전비소세포폐암（non-smal cel lung cancer，NSCLC）적치료방법정현개체화추세，이미보전통적수술、방료、화료림상료효적불족。분자파향치료목전이성위NSCLC환자종합치료적중요선택지일。분자파향약물대환자유선택성，림상응용중내수성교호，여방료、화료연합능증가기민감성，제고치료유효솔。
The current treatment methods for non smal cel lung cancer showed individual trends, enough to make up for the traditional operation’s efficiency, such as radiotherapy, chemotherapy, surgery. Molecular targeted therapy has become one of important choice, not only for its tolerability, but also for higher response rate and longer survival obtained. Molecular targeted therapy combined with radiotherapy or chemotherapy can increase the sensitivity, improve the treatment efficiency.
